6533b831fe1ef96bd1299b93

RESEARCH PRODUCT

Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a Phase II study

Gabriella FerrandinaAmelia PagliaM. ColangeloGiovanni ScambiaFrancesco LeggeVanda SalutariDomenica LorussoValerio GallottaAntonia Carla TestaFabio Fulfaro

subject

OncologyCancer ResearchPoor prognosisChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPhases of clinical researchmedicine.diseaseCarboplatinchemistry.chemical_compoundOrally activeOncologychemistryInternal medicinemedicineCelecoxibOvarian cancerbusinessRecurrent Ovarian Carcinomamedicine.drug

description

5060 Background: Cyclooxygenase-2 (COX-2) expression is associated with a poor chance of response to chemotherapy and poor prognosis in ovarian cancer (OC). Celecoxib, an orally active COX-2 inhibi...

https://doi.org/10.1200/jco.2005.23.16_suppl.5060